Newsroom / Industry / Industry / Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

DR Therapeutics Market is Forecast to Show Significant Growth from 2010 to 2017
Hyderabad, AP, India ( 24/02/2011
No disease-modifying therapies are currently approved for the treatment of DR and products such as LUCENTIS, Macugen and Avastin, which have disease-modifying properties, are used as off-label therapies but to a limited extent. However, GlobalData’s research indicates that the future product pipeline is strong with disease-modifying therapies such as LUCENTIS, Macugen, Arxxant and Nevanac in late-stage clinical development. The treatment landscape for DR has scope for disease-modifying drugs that are strong in terms of efficacy and safety. As physicians and patients become more aware of the latest technological developments, the key factors that will drive acceptance are improved efficacy, tolerability and safety profiles, as well as market penetration of pipeline products.

For Sample Pages, please click or add the below link to your browser:

According to GlobalData analysis, the current competition in the DR therapeutics market is weak. The market lacks therapies approved by the FDA (Food and Drug Administration) or the EMEA (European Medicines Agency) for the treatment of DR. The off-label use of drugs such as anti-VEGF (Vascular Endothelial Growth Factor) drugs in general aims to manage the conditions that contribute to the re-occurrence of DR, or make it worse. Lack of approved drugs has increased the use of surgical interventions.

GlobalData analysis shows that the DR therapeutic pipeline is strong, with approximately 45 molecules in various phases of clinical development. More importantly, 39 molecules are first-in-class molecules and have distinct advantages with respect to efficacy and safety profile These new drugs have the potential to fulfill the current unmet need of the market, and provide intense competition. This would also reduce the dependence on laser and surgical treatments.

GlobalData estimates that the global Diabetic Retinopathy (DR) therapeutics market was valued at $169m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 35.5% over the next seven years, to reach $1.41 billion by 2017. This high growth is largely due to the growth in the diabetes population and a strong pipeline which includes first-in-class drugs with disease-modifying properties as well as better safety and efficacy profiles. Approval of LUCENTIS (ranibizumab), Macugen (pegaptanib), Arxxant (ruboxistaurin) and Nevanac (nepafenac) is expected to drive the future market.

GlobalData, the industry analysis specialist, has released its new report, “Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Diabetic Retinopathy (DR) therapeutics market. The report identifies the key trends shaping and driving the global DR therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global DR therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:

Visit our report store:

For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782


GlobalData is a global market intelligence services company providing information research and analysis products and services.


Rajesh Gunnam

e-park, hyderabad
Zipcode : 500050